MÃ¡tyÃ¡s Keltai

List of Publications by Year
in descending order

24 papers	5,128 citations	586496 16 h-index	685536 24 g-index
24 all docs	24 docs citations	24 times ranked	7519 citing authors

#	Article	IF	Citations
1	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.	1.4	6
2	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17
3	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	1.0	18
4	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	5.5	17
5	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	5.5	77
6	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	2.7	14
7	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	4.9	123
8	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
9	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
10	Effects of blood pressure and lipid lowering on cognition. Neurology, 2019, 92, e1435-e1446.	1.5	54
11	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology, 2018, 34, 38-44.	0.8	13
12	Effects of Lipidâ€Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPEâ€3 Trial. Journal of the American Heart Association, 2018, 7, .	1.6	1
13	Design and baseline characteristics of participants in the <scp>R</scp>esearching cardiovascular <scp>E</scp>vents with a <scp>W</scp>eekly <scp>IN</scp>cretin in <scp>D</scp>iabetes (<scp>REWIND</scp>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	2.2	160
14	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
15	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	13.9	641
16	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
17	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. JAMA Cardiology, 2016, 1, 451.	3.0	137
18	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	0.8	24

#	Article	IF	Citations
19	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 86-94.	1.4	59
20	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	1.1	4
21	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, 4, e002490.	1.6	37
22	Amiodarone, Anticoagulation, andÂClinicalÂEvents in Patients WithÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2014, 64, 1541-1550.	1.2	84
23	Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 312-318.	3.1	110
24	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Nonâ€“Q-Wave Myocardial Infarction. Circulation, 2000, 102, 1014-1019.	1.6	688